National Heart and Lung Institute, Imperial College London, Du Cane Road, London W12, UK.
Department of Cardiology, Centre Hospitalier Universitaire de Rouen Charles Nicolle, Rouen, France.
Europace. 2023 May 19;25(5). doi: 10.1093/europace/euad019.
The field of conduction system pacing (CSP) is evolving, and our aim was to obtain a contemporary picture of European CSP practice.
A survey was devised by a European CSP Expert Group and sent electronically to cardiologists utilizing CSP. A total of 284 physicians were invited to contribute of which 171 physicians (60.2%; 85% electrophysiologists) responded. Most (77%) had experience with both His-bundle pacing (HBP) and left bundle branch area pacing (LBBAP). Pacing indications ranked highest for CSP were atrioventricular block (irrespective of left ventricular ejection fraction) and when coronary sinus lead implantation failed. For patients with left bundle branch block (LBBB) and heart failure (HF), conventional biventricular pacing remained first-line treatment. For most indications, operators preferred LBBAP over HBP as a first-line approach. When HBP was attempted as an initial approach, reasons reported for transitioning to utilizing LBBAP were: (i) high threshold (reported as >2 V at 1 ms), (ii) failure to reverse bundle branch block, or (iii) > 30 min attempting to implant at His-bundle sites. Backup right ventricular lead use for HBP was low (median 20%) and predominated in pace-and-ablate scenarios. Twelve-lead electrocardiogram assessment was deemed highly important during follow-up. This, coupled with limitations from current capture management algorithms, limits remote monitoring for CSP patients.
This survey provides a snapshot of CSP implementation in Europe. Currently, CSP is predominantly used for bradycardia indications. For HF patients with LBBB, most operators reserve CSP for biventricular implant failures. Left bundle branch area pacing ostensibly has practical advantages over HBP and is therefore preferred by many operators. Practical limitations remain, and large randomized clinical trial data are currently lacking.
心脏传导系统起搏(CSP)领域正在不断发展,我们的目的是了解欧洲 CSP 实践的现状。
由欧洲 CSP 专家组设计了一项调查,并以电子方式发送给使用 CSP 的心脏病专家。共邀请了 284 名医生参与,其中 171 名医生(60.2%;85%为电生理学家)做出了回应。大多数(77%)医生既有希氏束起搏(HBP)经验,也有左束支区域起搏(LBBAP)经验。CSP 的起搏适应证主要包括房室传导阻滞(无论左心室射血分数如何)和冠状窦导联植入失败。对于左束支传导阻滞(LBBB)和心力衰竭(HF)患者,传统的双心室起搏仍然是一线治疗方法。对于大多数适应证,操作者更倾向于将 LBBAP 作为一线治疗方法。当尝试作为初始方法进行 HBP 时,报告的转为使用 LBBAP 的原因包括:(i)阈值高(报道为 1ms 时>2V),(ii)未能逆转束支传导阻滞,或(iii)>30min 尝试在希氏束部位植入。用于 HBP 的备用右心室导联使用率较低(中位数为 20%),主要用于起搏-消融场景。在随访期间,12 导联心电图评估被认为非常重要。这一点,再加上当前捕获管理算法的局限性,限制了对 CSP 患者的远程监测。
这项调查提供了欧洲 CSP 实施情况的快照。目前,CSP 主要用于心动过缓的适应证。对于 LBBB 的 HF 患者,大多数操作者将 CSP 保留用于双心室植入失败。左束支区域起搏显然比 HBP 具有实际优势,因此许多操作者更喜欢使用左束支区域起搏。目前仍然存在实际限制,而且缺乏大型随机临床试验数据。